Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Zynerba Pharmaceuticals (Formerly AllTranz)

Request full access

Pharmaceutical products via dermal solutions to treat a various neuroscience disorders

Easttown Township, United StatesFounded 2007Biotech & Life Sciences

About Zynerba Pharmaceuticals (Formerly AllTranz)

Zynerba Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing innovative transdermal CBD therapies for patients with rare and near-rare neuropsychiatric disorders. The company's primary product candidate, Zygel, is a CBD gel designed to be applied to the skin, offering a non-invasive treatment option for conditions such as Fragile X Syndrome, Autism Spectrum Disorder, and 22q11.2 Deletion Syndrome. Zynerba operates in the biopharmaceutical market, targeting unmet medical needs in niche patient populations. The business model revolves around advancing clinical trials, securing regulatory approvals, and ultimately commercializing their therapies. Revenue generation is anticipated through product sales, partnerships, and potential licensing agreements.

Source: Dealroom company data

At a glance

Status
Acquired
Employees
9
Open positions
None listed
Dealroom signal
29.4/100
Industry
Health
Sub-industry
Pharmaceutical
Sector
Hard Tech, science-based, Oncology, DT and LS, Biotech and Pharma, Biotechnology
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITION✓Exit Aug 2023 $200M $200M Harmony Biosciences ↗
IPO✓Exit Aug 2015 $0 — Undisclosed —
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Zynerba Pharmaceuticals (Formerly AllTranz) website traffic

Latest recorded traffic for Zynerba Pharmaceuticals (Formerly AllTranz) is 330 monthly website visits, down 72.5% over the last three months. Zynerba Pharmaceuticals (Formerly AllTranz)'s team declined 67.9% over the past year.

Latest monthly visits330 3-month web change-72.5% 1-year team growth-67.9%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Zynerba Pharmaceuticals (Formerly AllTranz) in the Easttown Township ecosystem

Live from Dealroom

The Zynerba Pharmaceuticals (Formerly AllTranz) office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later1 investor entered at this stage

Other known investors1 additional known investor

  • Harmony Biosciences
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇺🇸 United States66.7%
🇦🇺 Australia22.2%
🇮🇪 Ireland11.1%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Zynerba Pharmaceuticals (Formerly AllTranz) on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Zynerba Pharmaceuticals (Formerly AllTranz)’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.